Short answer
Abbott Laboratories (ABT) filed an 8-K current report with the SEC on July 16, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Abbott reported second-quarter 2026 results on July 16, 2026.
Abbott Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Abbott reported second-quarter 2026 results on July 16, 2026
- Exhibit 99.1 contains the earnings release with detailed operating and financial results
- Adjusted earnings exclude acquisition costs, legal reserves, restructuring, regulatory costs, taxes and intangible amortization
- Investors should reconcile Abbott’s non-GAAP results with GAAP measures when assessing ongoing performance
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales $12.593B, up 13.0% reported and 4.8% comparable, showing acquisition and currency effects materially boosted headline growth
- Adjusted diluted EPS $1.31, up 4.0%, while GAAP EPS fell to $0.53 from $1.01 amid $1.362B in specified charges
- Full-year adjusted EPS guidance raised to $5.45 to $5.60 from $5.38 to $5.58, signaling confidence in second-half earnings momentum
- Diagnostics comparable sales grew 2.9%, including 13.3% cancer diagnostics growth, while rapid and molecular diagnostics declined 8.0%
- Medical Devices comparable sales grew 8.4%, led by electrophysiology at 13.4% and diabetes care at 9.0%; shareholder returns totaled $2.1B in Q2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Abbott Laboratories 8-K filings
Get the next ABT 8-K as it lands
Follow ABT for push alerts, or ask the research agent what this filing means.